Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Objectives To quantify out-of-pocket (OOP) costs and catastrophic health expenditure (CHE) among patients hospitalised with ...